Curis Inc
CRIS1.570USD
-0.060-3.68%
Market hours （ET）Quotes delayed by 15 min
16.43MMarket Cap
LossP/E TTM
More Details of Curis Inc Company
Curis, Inc. is a biotechnology company. The Company is focused on the development of emavusertib (CA-4948), an orally available, small molecule inhibitor of Interleukin-1 receptor associated kinase (IRAK4). Emavusertib is undergoing testing in the Phase I/II TakeAim Lymphoma study in patients with relapsed/refractory primary central nervous system lymphoma (PCNSL) in combination with the BTK inhibitor ibrutinib, as a monotherapy in the Phase I/II TakeAim Leukemia study in patients with relapsed/refractory acute myeloid leukemia (AML) and relapsed/refractory high risk myelodysplastic syndrome (hrMDS). Its other clinical programs include Fimepinostat and CA-170. Fimepinostat is an oral, dual inhibitor of histone deacetylase (HDAC), and phosphotidyl-inositol 3 kinase (PI3K) enzymes. CA-170 is an oral small molecule drug candidate that is designed to selectively target V-domain Ig Suppressor of T-cell Activation (VISTA) and PDL1 immune checkpoint proteins.
Company Info
Ticker SymbolCRIS
Company nameCuris Inc
IPO dateAug 01, 2000
CEOMr. James E. Dentzer
Number of employees33
Security typeOrdinary Share
Fiscal year-endAug 01
Address128 Spring Street
CityLEXINGTON
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code02421
Phone16175036500
Websitehttps://www.curis.com/
Ticker SymbolCRIS
IPO dateAug 01, 2000
CEOMr. James E. Dentzer
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. James E. Dentzer
Mr. James E. Dentzer
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
8.39K
+37.97%
Ms. Diantha Duvall
Ms. Diantha Duvall
Chief Financial Officer
Chief Financial Officer
4.90K
+660.71%
Dr. Kenneth I. Kaitin, Ph.D.
Dr. Kenneth I. Kaitin, Ph.D.
Independent Director
Independent Director
1.41K
--
Mr. Martyn D. Greenacre
Mr. Martyn D. Greenacre
Independent Chairman of the Board
Independent Chairman of the Board
1.30K
--
Dr. Jonathan Zung, Ph.D.
Dr. Jonathan Zung, Ph.D.
Chief Development Officer
Chief Development Officer
--
--
Dr. Anne Borgman, M.D.
Dr. Anne Borgman, M.D.
Independent Director
Independent Director
--
--
Dr. John A. Hohneker, M.D.
Dr. John A. Hohneker, M.D.
Independent Director
Independent Director
--
--
Dr. Marc Rubin, M.D.
Dr. Marc Rubin, M.D.
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. James E. Dentzer
Mr. James E. Dentzer
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
8.39K
+37.97%
Ms. Diantha Duvall
Ms. Diantha Duvall
Chief Financial Officer
Chief Financial Officer
4.90K
+660.71%
Dr. Kenneth I. Kaitin, Ph.D.
Dr. Kenneth I. Kaitin, Ph.D.
Independent Director
Independent Director
1.41K
--
Mr. Martyn D. Greenacre
Mr. Martyn D. Greenacre
Independent Chairman of the Board
Independent Chairman of the Board
1.30K
--
Dr. Jonathan Zung, Ph.D.
Dr. Jonathan Zung, Ph.D.
Chief Development Officer
Chief Development Officer
--
--
Dr. Anne Borgman, M.D.
Dr. Anne Borgman, M.D.
Independent Director
Independent Director
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Sat, May 17
Updated: Sat, May 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Bleichroeder LP
8.63%
Armistice Capital LLC
8.61%
Satterfield (Thomas A Jr)
7.39%
Maverick Capital, Ltd.
5.26%
M28 Capital Management LP
4.34%
Other
65.76%
Shareholders
Shareholders
Proportion
Bleichroeder LP
8.63%
Armistice Capital LLC
8.61%
Satterfield (Thomas A Jr)
7.39%
Maverick Capital, Ltd.
5.26%
M28 Capital Management LP
4.34%
Other
65.76%
Shareholder Types
Shareholders
Proportion
Investment Advisor
18.74%
Hedge Fund
16.28%
Individual Investor
7.53%
Venture Capital
1.66%
Investment Advisor/Hedge Fund
1.46%
Research Firm
0.78%
Other
53.54%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
101
5.57M
46.46%
+1.30M
2025Q1
112
5.58M
53.29%
+1.28M
2024Q4
119
3.88M
45.77%
+849.35K
2024Q3
129
2.03M
33.69%
-831.36K
2024Q2
151
2.33M
39.45%
-531.00K
2024Q1
226
2.12M
35.82%
-1.17M
2023Q4
249
2.07M
35.17%
-1.64M
2023Q3
265
2.42M
42.19%
-1.36M
2023Q2
279
1.78M
36.08%
-2.05M
2023Q1
312
1.73M
35.82%
-2.73M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Bleichroeder LP
1.04M
8.63%
+515.12K
+98.96%
Mar 31, 2025
Armistice Capital LLC
1.03M
8.61%
+957.37K
+1259.69%
Mar 31, 2025
Satterfield (Thomas A Jr)
886.71K
7.39%
+274.49K
+44.84%
Mar 31, 2025
Maverick Capital, Ltd.
631.83K
5.26%
--
--
Mar 31, 2025
M28 Capital Management LP
521.06K
4.34%
--
--
Mar 31, 2025
The Vanguard Group, Inc.
303.19K
2.53%
+32.94K
+12.19%
Mar 31, 2025
CM Management, LLC
240.00K
2%
+20.00K
+9.09%
Mar 31, 2025
Alyeska Investment Group, L.P.
189.38K
1.58%
-8.84K
-4.46%
Mar 31, 2025
Samsara BioCapital, LLC
185.94K
1.55%
-12.27K
-6.19%
Mar 31, 2025
Renaissance Technologies LLC
96.87K
0.81%
+2.80K
+2.98%
Mar 31, 2025
View more
Related ETFs
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Name
Proportion
iShares Micro-Cap ETF
0%
Avantis US Small Cap Equity ETF
0%
iShares Micro-Cap ETF
Proportion0%
Avantis US Small Cap Equity ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Sep 28, 2023
Merger
20<1
Sep 28, 2023
Merger
20<1
Sep 28, 2023
Merger
20<1
Sep 28, 2023
Merger
20<1
Date
Type
Ratio
Sep 28, 2023
Merger
20<1
Sep 28, 2023
Merger
20<1
Sep 28, 2023
Merger
20<1
Sep 28, 2023
Merger
20<1
